Amy Zalin

After initially pursuing a career in three-dimensional design and moving into the third sector, I was drawn into the world of statistics due to a passion for disease research particularly in cancer patients.

At HDI I focus mainly on epidemiological studies, collaborating with charities and industry to highlight inequalities and support the development of new treatments.

Outside of work I’m a keen runner, who when not running, can often be found trying to convince others to take up the hobby.


Amy Zalin-Miller

Senior Health Data Analyst


Amy trained in epidemiology at the London School of Hygiene and Tropical Medicine. Whilst there she primarily focussed on non-communicable diseases, using the CPRD database to research treatment changes, adherence to guidelines, and associated factors in COPD patients.

She has experience of working with clinical data directly in an acute trust setting, where at Great Ormond Street she managed the clinical data and analysis for bone marrow transplants, oncology, infectious diseases, rheumatology and immunology. 

Her in depth understanding of cancer datasets came from working within an NHS and Public Health England Partnership aiming to reduce inequalities in cancer across London.

These experiences led her to HDI where she works across several epidemiological studies. Her work includes developing real-world standing cohorts, where registration data are linked to treatment datasets to describe treatment pathways, outcomes and adverse effects as a population level comparator for novel therapeutics.


Education and awards: 

2017-18: London School of Hygiene and Tropical Medicine
– MSc in Epidemiology (Distinction)

2014-15: Birkbeck University of London
– Graduate Certificate in Applied Statistics

2006-09: Northumbria University Newcastle
– BA Hons (First Class) Three Dimensional Design

Selected Publications:

Elsada A., Zalin-Miller A., Knott C., Caravotas L. (2021) ‘A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England’ Wiley Online LIbrary eJHeam. June 2021.




Testing the Simulacrum

Testing the Simulacrum

Real-world Standing Cohorts

Real-world Standing Cohorts

Share This